PureTech Health (CHIX:PRTCL) FCF Margin % : -1,259.74% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is PureTech Health FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. PureTech Health's Free Cash Flow for the six months ended in Dec. 2024 was £-43.00 Mil. PureTech Health's Revenue for the six months ended in Dec. 2024 was £3.41 Mil. Therefore, PureTech Health's FCF Margin % for the quarter that ended in Dec. 2024 was -1,259.74%.

As of today, PureTech Health's current FCF Yield % is -34.12%.

The historical rank and industry rank for PureTech Health's FCF Margin % or its related term are showing as below:

CHIX:PRTCl' s FCF Margin % Range Over the Past 10 Years
Min: -14143 Med: -1644.13 Max: -280.86
Current: -3102.43

During the past 13 years, the highest FCF Margin % of PureTech Health was -280.86%. The lowest was -14143.00%. And the median was -1644.13%.

CHIX:PRTCl's FCF Margin % is ranked worse than
86.5% of 1000 companies
in the Biotechnology industry
Industry Median: -102.885 vs CHIX:PRTCl: -3102.43

PureTech Health FCF Margin % Historical Data

The historical data trend for PureTech Health's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health FCF Margin % Chart

PureTech Health Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-1,645.41

-1,642.84

-8,658.16

-14,143.00

-3,114.42

PureTech Health Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-9,703.59	-8,693.60	-	-	-1,259.74

Competitive Comparison of PureTech Health's FCF Margin %

For the Biotechnology subindustry, PureTech Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PureTech Health's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PureTech Health's FCF Margin % distribution charts can be found below:

* The bar in red indicates where PureTech Health's FCF Margin % falls into.

Save Embed

;

Save Embed

;

PureTech Health FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

PureTech Health's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-106.295	/	3.413
	=	-3,114.42 %

PureTech Health's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-42.995	/	3.413
	=	-1,259.74 %

PureTech Health FCF Margin % Related Terms

Thank you for viewing the detailed overview of PureTech Health's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

PureTech Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (CHIX:PRTCl) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

PRTC:USA PTCHF:USA PRTC:UK 0VQ:Germany

Address

6 Tide Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.puretechhealth.com

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

PureTech Health Headlines

No Headlines